Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) CEO Jennifer L. Good sold 10,981 shares of the firm's stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total value of $33,162.62. Following the transaction, the chief executive officer now directly owns 213,313 shares of the company's stock, valued at approximately $644,205.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Trevi Therapeutics Trading Up 5.1 %
Shares of TRVI traded up $0.15 during midday trading on Thursday, hitting $3.10. The stock had a trading volume of 281,977 shares, compared to its average volume of 235,572. The business has a 50-day simple moving average of $2.86 and a two-hundred day simple moving average of $2.86. The firm has a market cap of $218.35 million, a P/E ratio of -9.18 and a beta of 0.96. Trevi Therapeutics, Inc. has a fifty-two week low of $0.97 and a fifty-two week high of $4.00.
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.01). During the same period in the previous year, the business earned ($0.07) EPS. On average, analysts expect that Trevi Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.
Institutional Trading of Trevi Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the business. Frazier Life Sciences Management L.P. lifted its stake in Trevi Therapeutics by 7.3% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 7,381,090 shares of the company's stock worth $9,891,000 after acquiring an additional 500,000 shares in the last quarter. Opaleye Management Inc. lifted its position in shares of Trevi Therapeutics by 48.6% in the fourth quarter. Opaleye Management Inc. now owns 2,535,000 shares of the company's stock worth $3,397,000 after purchasing an additional 829,100 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new stake in shares of Trevi Therapeutics during the first quarter worth approximately $208,000. Vanguard Group Inc. grew its position in Trevi Therapeutics by 2.7% during the first quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company's stock valued at $7,948,000 after purchasing an additional 60,249 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD acquired a new position in Trevi Therapeutics in the 1st quarter valued at approximately $47,000. Institutional investors and hedge funds own 95.76% of the company's stock.
Analyst Upgrades and Downgrades
A number of brokerages have weighed in on TRVI. Raymond James began coverage on shares of Trevi Therapeutics in a report on Friday, August 30th. They issued an "outperform" rating and a $9.00 price target for the company. HC Wainwright started coverage on shares of Trevi Therapeutics in a research note on Friday, August 30th. They set a "buy" rating and a $6.00 target price for the company. Rodman & Renshaw started coverage on shares of Trevi Therapeutics in a report on Thursday, June 13th. They set a "buy" rating and a $7.00 target price for the company. EF Hutton Acquisition Co. I raised Trevi Therapeutics to a "strong-buy" rating in a report on Monday, August 19th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $8.00 price objective on shares of Trevi Therapeutics in a research report on Wednesday, May 8th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Trevi Therapeutics has a consensus rating of "Buy" and an average price target of $7.80.
Get Our Latest Research Report on TRVI
Trevi Therapeutics Company Profile
(
Get Free Report)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Trevi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.
While Trevi Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
